1329799-64-5
1329799-64-5
Chemical Structure
Piracetam-d8
- CAS No.: 1329799-64-5
- Formula:C6H2D8N2O2
- Molecular Weight:150.21
IUPAC Name: 2-(2-oxopyrrolidin-1-yl-3,3,4,4,5,5-d6)acetamide-2,2-d2
InChIKey: GMZVRMREEHBGGF-SVYQBANQSA-N
SMILES: C(C(N)=O)(N1C(=O)C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])([2H])[2H]
Biological Activity: Piracetam-d8 (UCB-6215-d8) is the deuterium labeled Piracetam. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Piracetam-d8 | Piracetam-d8 (UCB-6215-d8) is the deuterium labeled Piracetam. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piracetam (Standard) | 99.98% | Piracetam (Standard) is the analytical standard of Piracetam. This product is intended for research and analytical applications. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piracetam-d6 | Piracetam-d6 is deuterium labeled Piracetam. Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Piracetam | 98.57% | Piracetam (UCB-6215) is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Mingeot-Leclercq, M.P., et al., Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta, 2003. 1609(1): p. 28-38. [Content Brief]
